--:--:--
⬤ LOW 20 Nov 2026, 18:19 UTC

Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds

Walmart Inc. (NASDAQ:WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results. It reported an adjusted EPS of 65 cents, exceeding analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments. Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of $187.271 billion. However, Walmart’s weight-loss drug windfall is losing momentum despite rising prescription volumes. Analyst Price Forecast Revisions Several analysts raised their price forecasts following Walmart’s third-quarter results and increased guidance, while maintaining their existing ratings. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and raised his price forecast to $135 from $125. Piper Sandler analyst Peter Keith maintained an Overweight rating and increased his price forecast to $138 from $128. TD Cowen analyst Max Rakhlenko maintained a Buy rating and raised his price forecast to $147 from $125. Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased his price forecast to $134 from $114. BTIG analyst Robert Drbul reiterated a Buy rating and maintained his $140 price forecast. BTIG Analyst View Drbul believes Walmart’s underlying U.S. business remains healthy, although Health & Wellness (H&W) is expected to weigh on reported comparable sales. Walmart’s 2.9% U.S. comparable sales growth included an approximately 125-basis-point drag from Maximum Fair Price-related pharmacy deflation and brand-to-generic transfers, partly offset by a roughly 60-basis-point contribution from GLP-1 drugs. Excluding H&W, comparable sales increased 3.6%, slightly accelerating from the second quarter of fiscal 2027 and improving on a two-year basis. Looking ahead, the analyst expects healthy underlying demand but anticipates continued pressure on reported comparable sales from H&W. MFP-related headwinds are expected to remain near current levels or increase slightly, while the contribution from GLP-1 drugs is likely to moderate. However, improving H&W gross profit margins should help cushion the impact of weaker reported sales, according to the analyst. Earnings Estimates And Outlook Drbul maintained his fiscal 2027 EPS estimate at $2.90 but lowered his fourth-quarter Walmart U.S. comparable sales growth forecast to 2.9% from 3.1%. He expects comparable sales to increase 3.6% excluding H&W. The analyst expects fiscal 2027 net sales of $748 billion, representing approximately 6% year-over-year growth, with operating income projected to grow faster than sales. For fiscal 2028, Drbul raised his EPS estimate to $3.25 from $3.15. WMT Price Action: Walmart shares were up 2.82% at $129.60 at the time of publication on Friday, according to Benzinga Pro data. Read Also: Walmart CEO Sees Resilient Consumers, Bets on Strong Holiday Shopping Season Photo via Shutterstock 
\
Terms of Service